Benefits of nintedanib continuation in systemic autoimmune rheumatic disease-related progressive pulmonary fibrosis: KEIO-SARD-ILD-cohort
Continuation of nintedanib beyond 12 months, compared with discontinuation within 12 months, is associated with significant improvements in pulmonary function, biomarkers, and survival in patients with SARD-ILD-related PPF, suggesting that long-term nintedanib therapy plays a critical role in stabilizing disease progression.
Authors
- Yuko Kaneko (ORCID: https://orcid.org/0000-0003-2646-5765)
- Kanako Shimanuki (ORCID: https://orcid.org/0009-0006-0001-1078)
- Koji Suzuki (ORCID: https://orcid.org/0000-0003-1358-7069)
- Mitsuhiro Akiyama (ORCID: https://orcid.org/0000-0001-5075-8977)
- Hiroyuki Fukui (ORCID: https://orcid.org/0009-0004-8401-8044)
Institutions
- Keio University (JP)
Publication Details
- Journal
- Seminars in Arthritis and Rheumatism
- Published
- 2025-12-11
- DOI
- https://doi.org/10.1016/j.semarthrit.2025.152891
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00